In March 2025, the company declared new strategies for just a direct-to-client presenting of its Wegovy weight loss drug. The company set up a different pharmacy, known as NovoCare, which would charge consumers $499 every month for use of the drug, less than 50 % the expense of the drug by means of other pharmaceutical distribution networks.[53]inf